• MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported selling 43,700 Class A ordinary shares on July 20, 2026.
• Sale priced at USD 20.09 per share on a weighted-average basis.
• Indirect holdings fell to 2,764,746 shares following the transaction.
• Direct holdings totaled 35,389 shares after the sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-080133), on July 21, 2026, and is solely responsible for the information contained therein.